USC’s Keck School of Medicine partners with StemCardia to advance heart failure treatment

Post author:
Post published:October 8, 2024
Post category:uncategorized

The Keck School of Medicine of USC has launched a strategic collaboration with StemCardia, a biotechnology company, founded by a Keck School of Medicine faculty member, that develops cellular and genetic therapies to address heart failure.

Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.

Helpful Links

Subscribe To Us

By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy

UPCOMING EVENTS

You Might Also Like

New insights into how viruses disrupt heart function and lead to sudden cardiac deaths

Bio-Rad launches three StarBright Red Dyes and expands range of antibody markers conjugated to StarBright Violet Dyes to enhance immunology research

Food additive carrageenan (E 407) could disrupt the intestinal barrier and increase the risk of type 2 diabetes, study finds

Helpful Links

Subscribe To Us